Pharma: Clinic Roundup
Friday, October 4, 2013
• Abbvie Inc., of Chicago, shared results of a posthoc analysis of a Phase II study of Humira (adalimumab) for patients with hidradenitis suppurativa. The analysis showed that Humira produced a significant response rate in patients with moderate to severe disease at 16 weeks compared to placebo for the two dosing regimens assessed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.